Taibei, China – Recently, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") received the regulatory approval from Taiwan Food and Drug Administration ("TFDA") for its in-house developed Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®"). It is the second drug-eluting stent of MicroPort® that successfully gained the regulatory approval in Taiwan, following Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
Firebird2® is the second generation drug-eluting stent of MicroPort® for the treatment of coronary artery stenosis or occlusion. It is based on the new cobalt chromium alloy stent platform. It has good radial support force, excellent stent flexibility, and outstanding MRI compatibility.
With the increasing aging population, the incidence rate of coronary disease is constantly growing in Taiwan. According to statistics, there are around 30,000 PCI cases in the Taiwan market annually and the demand for coronary stent is rapidly increasing. As Firehawk® and Firebird2® both gained regulatory approval in Taiwan, MicroPort® further diversified its product offering in the local market. With its outstanding performance, it is expected that Firebird2® will provide more ideal cardiovascular treatment for the local patients.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.